Can the short aortic rim be a risk factor for developing migraine after percutaneous closure of secundumtype atrial septal defect?

Providência, A.; Silva, C. S.; Costa, Marco; Quintal, Nuno; Luzeiro, Isabel; Leitão‐Marques, António

doi:10.1097/00003643-200801001-00094

Cited by 2 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In terms of study type, change in preexisting MH was reported in 3 of 8 case studies (62, 70, 82); 2 of 3 prospective studies (71, 84), and in 9 of 13 retrospective studies (19, 52, 59–61, 63, 64, 76, 81). De novo MH was reported in 5 of 8 case studies (57, 73, 75, 78, 92), in 2 of 3 prospective studies (71, 72), and in 11 of 13 retrospective studies (19, 46, 51, 52, 58, 61, 64, 67, 77, 81, 93). Finally, a recent randomized controlled trial reported de novo MH following pASDC (79).…”

Section: Resultsmentioning

confidence: 99%

“…Additional highlights of this study are outlined in the preexisting MH section reviewing retrospective studies. Providencia et al ( 94 ) reported de novo MH in 3/25 patients (12%), each of whom had a morphological trait (short aortic rim) that significantly differed from other patients not experiencing MH after closure ( p = 0.036). Migraine resolved in 2/3 patients (67%) within 12 months.…”

Section: Resultsmentioning

confidence: 99%

“…De novo MH was reported in 10 of 13 retrospective studies (19, 46, 51, 52, 58, 61, 64, 67, 76, 93). Yew and Wilson (58) reported de novo MH in 2/25 (8%) patients after closure; symptoms were strongly suggestive of MA (IHS MH criteria were not referenced) and interpreted in this review as MA.…”

Section: Resultsmentioning

confidence: 99%

“…The potential occurrence of de novo MH in this context, which ranged between 10 and 18% in the current review, should be weighed against overall prognosis of MH after pASDC and of course the success rate of closure. In 19/25 or 76% of studies (and in most patients) resolution, improvement or indications for momentum in the direction of MH improvement was indicated within follow-up and the frequency and severity of both de novo and preexisting MH tended to diminish gradually approaching final follow-up from an early post pASDC peak (46, 52, 57–59, 61–65, 68, 70–72, 75, 77, 82, 85, 93). In addition, high rates of successful ASD closure (a 93% rate estimated across the data) and very low complication rates but rapid recovery have become earmarks distinguishing pASDC.…”

Section: Discussionmentioning

confidence: 99%

“…One study reported short aortic rim in de novo MH patients (68); another study reported significantly greater ASD/occluder size in both patients with preexisting MH change and in de novo MH patients (61); an additional study reported significantly larger ASD size and ASD length to occluder length ratio in de novo MH patients (72). Otherwise, clinical characteristics (e.g., Qp/Qs, ASD size, occluder size, etc.)…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Migraine Modulation and Debut after Percutaneous Atrial Septal Defect Closure: A Review

Leger

DeSouza

2017

Front. Neurol.

View full text Add to dashboard Cite

IntroductionChange in migraine headache (MH)—preexisting MH change or development of de novo MH—are known potential complications following percutaneous closure of atrial septal defect (ASD), but consensus on a causal trigger remains elusive.ObjectivesTo expose potential MH triggers linked, mainly by timing and occurrence, to the emergence of de novo MH or change in preexisting MH subsequent to percutaneous ASD closure (pASDC).MethodsThe literature was systematically searched for studies available in English reporting MH status after pASDC published between January 1, 1990 and November 15, 2015. We determined the number and percentage of patients experiencing MH status change within 7 days post procedure and the cumulative total by final follow-up (Mdn = 12 months).ResultsTwenty-five studies met the inclusion criteria, which accounted for a total of 1,646 pASDC patients. Pre-procedure MH prevalence was 8% (126/1,646). Change in preexisting MH occurred in a total of 72% (91/126), 12% (11/91) within 7-days after pASDC; within follow-up MH improved in 14% (18/126), resolved in 37% (47/126), but persisted in 63% (79/126). De novo MH incidence ranged between 10 (153/1,520) and 18.3% (153/836); 34% incipience (52/153) was within 7-days of pASDC; females accounted for 80% (63/79) of gender differentiated cases; of type distinguished cases, 42% (51/122) were MH without aura (MO) and 58% (71/122) were MH with aura (MA); MH improved in 10% (16/153), resolved in 24% (37/153) but persisted beyond final follow-up in 76% (116/153). Antiplatelet agents were effective modulators of MH in 44% (11/25) studies. Possible adverse MH-predisposing traits were scarce: larger ASD size reported in ~2% (39/1,646) of patients experiencing de novo MH or preexisting MH exacerbation; short aortic rim reported in three de novo MH patients; allergic response to occluder nickel alloy in four patients with MH status change from baseline (de novo or preexisting MH change not specified).InterpretationEarly intensification of MH status change but later amelioration (virtually paralleling stages of endothelialization), relatively high efficacy of antiplatelet agents, and the emergence of MA as the dominant de novo MH type favor proinflammatory triggers of MH status change after pASDC.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Migraine Modulation and Debut after Percutaneous Atrial Septal Defect Closure: A Review

Leger

DeSouza

2017

Front. Neurol.

View full text Add to dashboard Cite

show abstract

Headache and Cardiovascular Disease: Old symptoms, New Proposals

Providência

2010

Future Cardiol.

View full text Add to dashboard Cite

Evidence of a link between headache symptoms and cardiovascular disease has rapidly grown in recent years and it is of utmost importance for the cardiologist and neurologist to be aware of this intimate connection. A brief overview of different cardiovascular diseases (namely hypertension, stroke, coronary heart disease, patent foramen ovale, atrial septal defects, atrial septal aneurisms, mitral valve prolapse, and aortic and carotid disease) that may be related to headache is presented in this article. Proposed pathophysiological mechanisms for this association and landmark studies are reviewed and discussed.

show abstract

Can the short aortic rim be a risk factor for developing migraine after percutaneous closure of secundumtype atrial septal defect?

Cited by 2 publications

References 0 publications

Migraine Modulation and Debut after Percutaneous Atrial Septal Defect Closure: A Review

Migraine Modulation and Debut after Percutaneous Atrial Septal Defect Closure: A Review

Headache and Cardiovascular Disease: Old symptoms, New Proposals

Contact Info

Product

Resources

About